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 Abstract   
Objective: The aim of the study was to evaluate the effect of etanercept immunotherapy on peripheral natural killer 
(NK) cell activity in women with a history of recurrent miscarriage (RM) or failed in vitro fertilization (IVF). 
Materials and methods: Thirty nonpregnant women with reproductive failure and increased peripheral NK-cell 
number and/or activity before conception were studied. Women with reproductive failure received 4 doses (25 mg) 
of etanercept twice weekly before conception. Peripheral NK-cell activity before and after etanercept therapy in RM 
women was measured using flow cytometry. In addition, the peripheral blood NK-cell surface antigens- CD16- and 
CD56 and peripheral blood regulatory T cell (T reg) antigens- CD4- and CD25 were studied using flow cytometry, 
before treatment and 2 weeks after the last etanercept dose.
Results: NK-cell activity was significantly decreased after etanercept therapy in the study women (P<.05). This effect 
was significantly higher in women with subsequent pregnancy success (P<.05), but not in those with pregnancy 
failure (P>.05). There were no significant differences in T reg level before and after etanercept therapy (P>0.05).
Conclusion: Etanercept therapy might be effective treatment for women with increased NK-cell activity. Regulation 
of immune system activity may underlie the possible effect of such therapy.
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Introduction
Etanercept	 (trade	 name	 Enbrel)	 is	 a	 drug	 that	 treats	
autoimmune	 diseases	 by	 interfering	 with	 the	 tumor	 necrosis	
factor	(TNF)	by	acting	as	a	TNF	inhibitor	[1-4].	Etanercept	is	a	
TNF	antagonist	with	anti-inflammatory	effects.	Its	major	mode	
of	 action	 is	 to	 suppress	TNF-α,	 a	 Th-1	 embryotoxic	 cytokine	
produced	 by	 activated	 natural	 killer	 cells	 (NK	 cells)	 [1-4].	
Etanercept	 is	 a	 fusion	 protein	 produced	 through	 expression	 of	
recombinant	DNA.	That	 is,	 it	 is	a	product	of	a	DNA	construct	
engineered	 to	 link	 the	human	gene	for	soluble	TNF	receptor	2	
to	 the	 gene	 for	 the	 Fc	 component	 of	 human	 immunoglobulin	
G1	 (IgG1).	Expression	of	 the	 construct	 produces	 a	 continuous	
protein	“fusing”	TNF	receptor	2	to	IgG1.	It	is	a	large	molecule,	
with	a	molecular	weight	of	150	kDa,	 that	binds	 to	TNF-α	and	
decreases	its	role	in	disorders	involving	excess	inflammation	in	
humans	and	other	animals,	including	autoimmune	diseases	such	
as	ankylosing	spondylitis,	juvenile	rheumatoid	arthritis,	psoriasis,	
psoriatic	 arthritis,	 rheumatoid	 arthritis,	 and,	 potentially,	 in	 a	
variety	of	other	disorders	mediated	by	TNF-α	excess	[1-4].
Recent	studies	suggest	that	etanercept,	while	blocking	TNF-α	
release,	may	also	deactivate	NK	cells	[1-4].	If	this	indeed	proves	
to	be	correct,	etanercept	might	be	effective	in	the	treatment	of	in	
vitro	fertilization	(IVF)	failure	and	recurrent	miscarriage	(RM)	
patients	with	NK-cell	activation.	Elevated	numbers of	peripheral	
blood	NK	cells	and	increased	infiltration	of	endometrial NK	cells	
have	been	reported	as	complications	related	to	pregnancy	[5,	6].	
Cellular	 immune	 abnormalities	 with	 increased	 peripheral 
blood	NK-cell	numbers	in	women	who	experienced	implantation 
failures	after	documented	embryo	transfer	or	recurrent	pregnancy 
losses	 have	 been	 reported	 [5,	 6].	 NK	 cell	 activity	 may	 also	
predict	pregnancy	loss	[6].	Although	the	immunophenotypes	of	
the	majority	of	peripheral	blood NK	cells	are	different	from	those	
of	endometrial	NK	cells,	peripheral blood	NK	cells	seem	to	be	
closely	related	to	decidual	NK	cells and	may	reflect	the	decidual	
NK-cell	functional	status	[7].	It	is	now	also	accepted	that	uterine	
NK	cells	are	at	least	partially	derived	from	blood	[7].	
Additionally,	 some	 data	 suggest	 that	 women	 with	 RM	
have	 altered	 peripheral	 blood	 NK	 parameters	 and	 NK	 cells	
as	 a	 percentage	 of	 lymphocytes	 best	 discriminate	 RM	 and	
control	 women	 [8-10].	 NK	 cell	 alteration	 may	 be	 associated	
with	impaired	pregnancy,	and	the	modulation	of	the	number	of	
circulating	NK	cells	is	most	likely	to	be	a	primary	event	in	the	
pathogenesis	of	 immunological	 infertility	 [11].	T	regulatory	(T	
reg)	cells	are	a	subset	of	T-cells	with	potent	suppresive	activity	
and	pivotal	roles	in	curtailing	destructive	immune	responses	and	
preventing	autoimmune	disease,	and	may	be	used	as	a	new	target	
for	infertility	treatment	[12].
Our	 previous	 case	 report	 indicated	 that	 etanercept	
immunotherapy	may	allow	a	successful	pregnancy	outcome	after	
multiple	IVF	failure	[13]. The	aim	of	this	study	was	to	determine	
etanercept	 immunotherapy	 influence	 on	 NK	 cells’	 activity	 in	
women	with	a	history	of	at	least	three	RM	or	failed	IVF.
Materials 
Patients
Thirty	 women	 with	 increased	 NK	 cell	 number	 and/or	
activity	before	were	studied.	Among	women	with	reproductive	
failure,	17	had	at	least	three	RM	and	13	at	least	three	IVF	failures	
(Table	I).	Women	received	4	doses	(25mg)	of	etanercept	 twice	
weekly	 before	 conception.	 Two	 women	 were	 excluded	 from	
the	 final	 analysis	 since	 they	 refused	 to	 have	 the	 peripheral	
blood	assay	re-checked	after	etanercept	therapy.	There	were	no	
significant	differences	among	RM	and	IVF	women	with	regard	
to	their	age	or	any	of	the	studied	parameters	(P>0.05)	except	the	
number	of	reproductive	failures,	which	was	significantly	higher	
in	IVF	women	(P<0.05),	(Table	I).	Consent	for	the	study	from	
the	Bioethics	Committee	 of	 the	Military	 Institute	 of	Medicine	
and	 from	 the	patients	was	obtained.	Natural	killer	 cell	 activity	
was	measured	using	flow	cytometry.	In	addition,	the	peripheral	
blood	NK	cell	surface	antigens-	CD16-	and	CD56	and	T	reg	were	
studied	using	flow	cytometry,	before	treatment	and	2	weeks	after	
the	last	etanercept	dose.
 Streszczenie   
Cel pracy: Celem pracy była ocena wpływu etanerceptu na aktywność komórek NK krwi obwodowej u kobiet 
z poronieniami nawykowymi (RM) lub wielokrotnymi niepowodzeniami zapłodnienia pozaustrojowego (IVF).
Materiał i metody: Badaniem objęto 30 kobiet z niepowodzeniami rozrodu i zwiększoną liczbą i/lub aktywnością 
komórek NK krwi obwodowej. Chore otrzymały 4 dawki (25mg) etanerceptu dwa razy w tygodniu przed planowaną 
ciążą. Aktywność komórek NK zbadano przed i po podaniu leku metodą cytometrii przepływowej. Dodatkowo 
oceniono ekspresję markerów powierzchniowych komórek NK CD16- i CD56 oraz limfocytów T regulatorowych (T 
reg) CD4- i CD25 metodą cytometrii przepływowej przed leczeniem oraz 2 tygodnie po ostatniej dawce leku.
Wyniki: Aktywność komórek NK była znamiennie zmniejszona po podaniu etanerceptu w grupie badanych chorych 
(P<0,05). Efekt ten był znamiennie wyższy u kobiet, których ciąże zakończyły się sukcesem położniczym (P<0,05), 
efektu tego nie zaobserwowano u kobiet z niepowodzeniem położniczym po podaniu etanerceptu (P>0,05). 
Nie stwierdzono różnic znamiennych statystycznie w ekspresji T reg w grupie badanej po podaniu etanerceptu 
(P>0,05).
Wnioski: Etanercept może być efektywną opcją terapeutyczną u kobiet ze zwiększoną ekspresją komórek NK. 
Regulacja aktywności układu immunologicznego może leżeć u podstaw skuteczności tej eksperymentalnej terapii.
 Słowa kluczowe: aktywność komórek NK / etanercept / poronienia nawykowe / 
     / zapłodnienie pozaustrojowe /   
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All	 tests	were	performed	at	 least	 six	months	 after	 the	 last	
miscarriage	or	IVF	failure.	The	women	were	informed	of	the	aim	
of	the	study	and	the	best	interests	of	participating	patients	always	
outweighed	those	of	 the	 trial.	All	measurements,	 interventions,	
and	blood	collections	were	performed	after	informed	consent	was	
obtained	from	each	woman	participating	in	the	study	in	accordance	
with	the	bioethics	committee-approved	protocol.	Consent	for	the	
study	 from	 the	 Bioethics	 Committee	 of	 the	 Military	 Institute	
of	 Medicine,	 Warsaw,	 and	 Institutional	 Review	 Board	 (IRB)	
approval	were	obtained.	All	data	obtained	from	the	subjects	were	
confidential	 and	accessible	only	 to	 the	 investigative	personnel.	
Recurrent	miscarriage	was	defined	as	three	or	more	consecutive	
pregnancy	 losses	 before	 20th	 week	 of	 gestation	with	 the	 same	
partner,	according	to	the	definition	formulated	by	Committee	for	
Diagnosis	 and	Treatment	 of	 Recurrent	 Spontaneous	Abortions	
[14]. 
All	women	were	investigated	in	terms	of	any	possible	causes	
of	 abortion,	 and	 no	 apparent	 reason	 for	 their	 previous	 losses	
was	 found.	Anatomic,	 genetic,	 microbiological,	 and	 hormonal	
causes	 of	 abortions	 or	 infertility	 were	 studied.	 A	 complete	
medical,	 surgical	 and	 social	 history	was	 obtained	 in	 all	 cases.	
Also,	all	couples	had	peripheral	blood	chromosome	assessment.	
Hysterosalpingography	 or	 hysteroscopy	 did	 not	 reveal	 any	
abnormalities	of	the	patient’s	uterus.	Levels	of	thyroid-	stimulating	
hormone	and	prolactin	were	normal. We	investigated	the	existence	
of	inherited	(deficiencies	of	protein	C,	protein	S,	antithrombin	III,	
resistance	 to	activated	protein	C	 including	Leiden	V	mutation,	
prothrombin	gene	mutation,	hyperhomocysteinemia)	or	acquired	
thrombophilia	 (anticardiolipin	 antibodies,	 lupus	 anticoagulant,	
beta-2-glycoprotein	 antibodies).	We	 also	 studied	 the	 existence	
of	 autoimmunity,	 i.e.	 antinuclear	 antibodies	 and	 antithyroid	
antibodies.	Nine	study	women	have	polycystic	ovary	syndrome	
(PCOS)	and	6	women	have	subclinical	thyroid	deficiency.
After	 the	diagnostic	procedure,	 the	patients	were	 asked	 to	
participate	 in	 our	 program.	 During	 this	 time	 no	 other	 therapy	
was	introduced.	After	finishing	etanercept	therapy,	we	introduce	
additional	 immunotherapy:	 heparin/aspirin,	 aspirin	 alone,	
steroids	or	combined	therapy	according	to	the	presence	of	auto-	
or	alloimmunity.	The	treatment	protocol	included	aspirin	75-100	
mg	starting	on	day	1	of	 the	cycle	and	prednisone	5mg	starting	
on	 day	 16	 of	 the	 cycle.	 Once	 pregnancy	 occured	 the	 dose	 of	
prednisone	was	increased	to	10	mg	every	evening	and	stopped	at	
14	weeks	and	aspirin	was	discontinued	at	36	weeks	of	gestation.	
In	 addition,	 enoxaparin	 (Clexane)	 40	 mg	 was	 administered	
subcutaneously	during	gestation.	Metformin	usually	1.5g	daily	
was	 introduced	 at	 least	 12	 weeks	 before	 pregnancy	 and	 this	
therapy	was	continued	during	pregnancy	at	1.0g	daily	in	PCOS	
patients.	We	noted	allergic	skin	reaction	in	the	etanercept	injection	
site	in	one	study	woman.	All	babies	born	after	etanercept	therapy	
were	healthy	except	one	with	cardiac	defect-atrial	septal	defect	
(ASDI)	corrected	at	age	6	month.	Now	the	boy	is	a	two-year	old,	
normal,	healthy	child.	Mother	of	this	boy	has	born	healthy	child	
in	her	next	pregnancy	under	the	same	therapy.
Methods
Peripheral	 blood	 NK-cell	 activity	 was	 measured	 using	
flow	cytometry	[10,	15].	The	peripheral	blood	NK-cell	surface	
antigens	CD16	 and	CD56,	 and	 peripheral	 blood	T	 reg	 surface	
antigens	CD4	and	CD25	were	also	studied	using	flow	cytometry	
(Simultest	 CD3/CD16+CD56,	 CD4/CD25,	 FACSCalibur,	
Cell	 Quest	 software,	 Becton-Dickinson,	 San	 Jose,	 CA,	 USA).	
Measurements	 were	 performed	 before	 etanercept	 therapy	 and	
two	weeks	after	the	last	dose	of	the	drug.
Endpoints
Primary	 endpoints	were	 peripheral	 blood	NK-cell	 activity	
and	T	reg	percentage	(before	and	after	etanercept	therapy).
Secondary	endpoints	were	pregnancy	outcome	in	the	study	
group.
NK assay
Separations of effector cells
Peripheral	 blood	 mononuclear	 cells	 (PBMC)	 were	
isolated	 from	 heparinized	 blood	 of	 patients	 by	 Ficoll	 gradient	
centrifugation.	 The	 mononuclear	 cells	 were	 adjusted	 to	 1x107 
cells/2.6	mL	in	culture	medium	(RPMI	1640,	10%	FBS).	Target	
cells	were	human	erythroleukemia	K562	(ATTC,	UK).	The	K562	
human	erythroleukemia	cell	line	is	used	as	a	standard	target	for	
human	NK-cell	assays.	The	K562	cells	were	washed	in	PBS	120g	
and	 labeled	with	 1.2mL	DIO	 (3,3-dioctadecyloxacarbocyanine	
perchlorate	(Sigma)	per	1mL	PBS	and	incubated	for	20	minutes	in	
5%	CO2 at	37
0C.	After	two	washes	in	PBS,	the	cell	concentration	
was	 adjusted	 to	 1x106	 cells/mL	 in	medium	 (RPMI	1640,	 10%	
FBS)	and	used	for	the	cytotoxicity	assay.
Cytotoxicity assay
Groups	of	eight	replicate	wells	were	incubated	for	4	hours	
in	5%CO2 at	37
0C:	PBMC	in	medium,	K562	in	medium,	mixed	
PBMC	with	target	cells	in	ratios	of	50:1	and	12:1.	Twenty-five	
microliters	 of	 propidium	 iodide	 solution	 (0.1	µg/mL	 in	water;	
Sigma)	was	added	to	each	sample	to	stain	dead	cells	(total	volume	
in	each	sample	0.2	mL).	
Live	 target	 cells	 (T)	 were	 identified	 by	 strong	 green	
fluorescence,	 whereas	 dead	 target	 cells	 (Td)	 showed	 strong	
green	and	red	fluorescence.	The	percentage	of	dead	target	cells	
(%Td)	was	calculated	by	%Td=(Td/T)	x	100.	Specific	lysis	was	
calculated	 by	 %Td	 cultured	 with	 effector	 cells-%Td	 cultured	
without	effector	cells.
Statistical analysis
All	of	 the	data	were	analyzed	using	Student’s	 t	 test	or	 the	
Mann-Whitney	 test	 for	 comparison	 of	 two	 groups	 or	Kruskal-
Wallis	 analysis	 of	 variance	 for	 comparison	 of	 a	 few	 groups;	
P<0.05	was	considered	to	be	statistically	significant.	Data	were	
processed	 using	 Statistical	 Analysis	 System	 (SAS)	 version	 8	
(SAS	Institute,	Cary,	NC).
Results
We	determined	that	16	of	28	women	(57.2%)	had	successful	
pregnancy	outcomes	and	6	of	28	(21.4%)	had	failures.	Six	of	the	
28	women	(21.4%)	women	did	not	attempt	to	achieve	their	next	
pregnancy	 by	 the	 end	 of	 this	 study.	There	were	 no	 significant	
differences	in	any	study	parameters	between	RM	women	when	
compared	 with	 IVF (P>0.05) except	 the	 number	 of	 previous	
reproductive	failures	(P<0.007),	(Table	I).
Peripheral	blood	NK-cell	activity	was	significantly	decreased	
after	etanercept	therapy	compared	with	NK-cell	activity	before	
therapy	in	the	study	group	(P<0.0008),	(Table	II).	
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There	were	no	significant	differences	when	comparing	NK-
cell	 activity	 in	 women	 with	 pregnancy	 success	 to	 those	 with	
pregnancy	failure	(P>0.05).	However,	this	effect	was	significantly	
higher	in	women	with	subsequent	pregnancy	success	(P<.008), 
but	 not	 in	 those	 with	 pregnancy	 failure	 (P>0.05),	 (Table	 III).	
There	were	no	significant	differences	in	T	reg	level	in	the	study	
group	before	and	after	etanercept	therapy	(P>0.05),	(Table	I).
Discussion
An	 anti-TNF-α	 therapy	 is	 considered	 a	 category	 B	 drug	
for	pregnancy.	Data	in	humans	are	limited	with	regard	to	safety	
for	pregnancy	[1-4,	16-18].	So	far,	 there	has	been	no	evidence	
that	 TNF-α	 antagonists	 are	 associated	 with	 embryo	 toxicity,	
teratogenicity	or	increased	pregnancy	loss	[1-4]. 
Some	 data	 suggest	 that,	 anti-TNF	 agents	 used	 during	
pregnancy	 in	 patients	 with	 rheumatic	 diseases	 may	 increase	
congenital	 anomalies	 comprising	 the	 association	 of	 vertebral	
abnormalities,	 anal	 atresia,	 cardiac	 defect,	 tracheoesophageal,	
renal,	 and	 limp	 abnormalities	 (VACTERL)	 [1-4].	 However,	
the	VACTERL	claim	was	 rubbished	by	Koren	and	 Inoue	 [16].	
The	most	complete	database	on	etanercept	 in	pregnancy	 is	 the	
OTIS	registry,	and	when	last	reported,	there	was	no	statistically	
significant	 increase	 in	 anomalies	 in	 rheumatologic	 patients	
talking	 the	drug	 in	 the	first	 trimester,	 and	no	evidence	 for	 any	
particular	type	of	abnormality	[17].	However,	current	guidelines	
suggest	 that	TNF-α	 blockers	 should	be	 avoided	 at	 the	 time	of	
conception	in	women	with	rheumatoid	arthritis	[18].	
In	our	study,	etanercept	was	safe	both	for	the	mothers	and	
for	the	babies.
Table I. Characteristics of the study groups: in vitro fertilization (IVF) group (n=12) and recurrent miscarriage (RM) group (n=16). aP<0.05. 
Variable Median Lower quartile
Upper 
quartile Minimum Maximum
Before 22.00a 9.00 28.00 0.00 43.00
After 11.00 6.00 15.00 2.00 39.50
Difference -7.00 -19.00 -1.00 -37.00 13.50
Table II. Peripheral blood natural killer cell activity (%) in the study group (n=28) before and after etanercept therapy. aP<0.05. 
Variable Median Lower quartile
Upper 
quartile Minimum Maximum
Before 21.00a 7.50 32.00 3.00 43.00
After 12.00 6.00 15.00 2.00 39.50
Difference -6.00 -20.00 -1.00 -37.00 7.00
Table III. Peripheral blood natural killer cell activity (%) in the group with subsequent successful pregnancy outcome (n=16) before and after etanercept therapy. aP<0.05. 
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Anti-TNF-α	 therapy	 can	 reset	 the	 immune	 system	 at	 a	
lower	 level	 of	 activity.	 Some	 data	 suggest	 that	 etanercept	 can	
exert	adverse	effects	of	inflammation	mediated	through	elevated	
TNF-α	 activity	 and	 TNF-α-independent	 pathways,	 including	
the	stress	hormone	response,	 factors	connected	 to	reproductive	
failure	 [19].	Etanercept	may	 control	 proinflammatory	 cytokine	
expression	 [20].	According	 to	 recent	 data	 pregnancy	 loss	 was	
prevented	 by	 blocking	 TNF-α	 activity	 after	 treatment	 with	
etanercept	in	an	animal	model	[21].	The	association	of	success	
with	 correction	 of	 immune	 test	 abnormalities	 by	 anti–TNF-α 
blockers	including	etanercept	or	adalimumab	has	been	reported,	
which	 was	 also	 shown	 by	 Winger	 [22-23].	 According	 to	 a	
recent	review	by	Clark,	anti-TNF-α	 therapy	appears	promising	
for	 treatment	of	 immune-mediated	subfertility	 [24].	Some	data	
suggest	 that	 etanercept	 promotes	 fertility	 since	 overproduction	
of	TNF-α	in	the	uterine	lining	by	NK	cells	impairs	implantation	
[25].	 The	 effectiveness	 of	 such	 therapy	 may	 derive	 from	
regulation	 of	 immune,	 inflammatory,	 and/or	 procoagulant	
pathways	 that	 collaborate	 in	 the	 pathogenesis	 of	 pregnancy	
failure.	According	to	a	recent	paper	by	Thaher	et	al.,	etanercept	
significantly	decreased	the	activation	marker	CD	69	expression	
by	CD56+NK-cells	[26].	
According	 to	 current	 knowledge	 NK-cell	 involvement	 in	
pathogenesis	of	pregnancy	loss	is	controversial,	but	in	our	study	
etanercept	 therapy	 promoted	 successfull	 pregnancy	 through	
diminished	 NK-cell	 activity	 [27].	 As	 recurrent	 miscarriage	
and	 infertility	encompassed	a	heterogeneous	group	of	patients,	
it	 would	 be	 important	 to	 fully	 characterize	 such	 patients	
immunologically	before	proceeding	with	further	studies.	As	yet,	
such	parameters	 do	not	 exist	 in	 clinical	 practice.	 In	our	 study,	
there	were	no	differences	between	IVF	and	RM	women	at	least	in	
the	NK	cell	and	T	reg	populations.	An	observational	study	could	
be	 done	 to	 identify	 the	 subgroups	most	 likely	 to	 benefit	 from	
treatment,	and	then	a	proper	multicenter	randomized	controlled	
trial	in	such	patients	would	be	appropriate.
Conclusion
Etanercept	therapy	might	be	effective	treatment	for	women	
with	 increased	NK-cell	 activity.	Regulation	of	 immune	system	
activity	may	underlie	the	possible	effect	of	such	therapy.
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